NCT01881126View on ClinicalTrials.gov

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

bimatoprost 0.01%

Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.

DRUG

travatan 0.004%

Travatan 0.004% administered to both eyes once daily for 12 weeks.

DRUG

timolol 0.5%

Timolol 0.5% administered to both eyes once daily for 12 weeks.

DRUG

hypromellose 0.3%

Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.

Trial Locations (2)

Unknown

Barrie

Toronto

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT01881126 - An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter